Role of leukemia inhibitory factor in nasopharyngeal carcinogenesis

Shu Chen Liu, Yu Sun Chang*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Although Epstein-Barr virus-associated nasopharyngeal carcinoma (NPC) is a highly radiosensitive cancer, approximately 20% of patients with NPC develop local recurrence after radiation therapy. Multiple proinflammatory cytokines are thought to protect NPC tumor cells from immune surveillance and therapeutic interventions. The cytokine leukemia inhibitory factor (LIF) is a critical component of the NPC microenvironment. LIF influences tumor growth and survival, and is therefore considered a potential therapeutic target and/or prognostic predictor for NPC. High LIF levels have been detected in the circulating blood of patients with recurrent NPC and NPC tumor cells. This review discusses the molecular mechanisms that link LIF to NPC tumor progression and radioresistance.

Original languageEnglish
Article numbere29900
JournalMolecular and Cellular Oncology
Issue number1
StatePublished - 01 01 2014

Bibliographical note

Publisher Copyright:
© 2014, Copyright © 2014 Landes Bioscience.


  • Epstein-Barr virus
  • leukemia inhibitory factor
  • mTOR
  • nasopharyngeal carcinoma
  • p70S6K
  • radioresistance


Dive into the research topics of 'Role of leukemia inhibitory factor in nasopharyngeal carcinogenesis'. Together they form a unique fingerprint.

Cite this